Votrient is a multi-targeted tyrosine kinase inhibitor and it is currently approved for renal cell carcinoma. To my knowledge there are no published studies supporting its use for urothelial cancer. An ongoing Phase-II trial Pazopanib ( Votrient ) for metastatic urothelial cancer has generated promising but very preliminary early results, reproted in ESMO 2010.
Researchers have enrolled 18 patients of a total of 41 planned. Each participant had metastatic urothelial cancer that had already failed to respond to at least one prior chemotherapy regimen. Patients were administered 800 mg of the drug once daily until their disease progressed or they experienced unacceptable toxicity.
Four patients have tumor response and twelve out of eighteen, saw necrosis of metastatic lesions on CT. These early results are promising but very preliminary
Vaishampayan U Systemic therapy of advanced urothelial cancer. Curr Treat Options Oncol., 10(3-4):256-66. Apr 29, 2009.
nccn.org, BLadder Cancer